Organon: FDA Extends Vtama Atopic-Dermatitis Review to March

WSJ11/05 21:00

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

GlobeNewswire10/30 04:35

Press Release: Organon Completes Acquisition of Dermavant, Including Innovative Dermatologic Therapy, VTAMA(R) (Tapinarof) Cream, 1%

Dow Jones10/28 21:25

Dermavant Presents Final Data From ADORING 3 LTE Study On VTAMA Cream, 1% At 2024 Fall Clinical Dermatology Conference; 51.9% Achieved Complete Disease Clearance And Remained Treatment-Free For ~80 Days; FDA PDUFA Action Date Expected Q4 2024

Benzinga10/25 20:06

Roivant Sciences Insider Sold Shares Worth $1,165,000, According to a Recent SEC Filing

MT Newswires10/23 15:15

Editas, Roivant's Genevant to Develop Gene Editing Therapies

Seeking Alpha10/22 05:33